Funding Daily Summary
Funding Daily Summary: What Happened on November 10, 2026
Delix raises $100 million to advance zalsupindole
Oyster raised $60 million for tau-targeting brain drugs, while Neobe secured $6.8 million for its engineered-bacteria cancer program.
Today in brief
Delix Therapeutics raised $100 million in a Series C and plans to move zalsupindole toward a placebo-controlled Phase II trial in early 2027.1 Oyster raised $60 million for tau-targeting brain drugs. Neobe raised $6.8 million to advance its engineered-bacteria cancer program.23
Also worth knowing
-
Oyster raised $60 million for brain drugs targeting tau. The company says its adaptation of protein-degradation technology may help break down the protein.2
-
Neobe Therapeutics raised $6.8 million in seed funding, led by ARC Ventures, to advance NEO22 through preclinical development. The company targets an investigational new drug application in 2028.3
-
Delix Therapeutics raised an oversubscribed Series C co-led by JJDC and the Dementia Discovery Fund. The company plans to advance zalsupindole toward a placebo-controlled Phase II trial in early 2027.1